Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2021
Reporting Period: Event date of February 11, 2021, with expected closing on February 16, 2021.
The filing reports the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the capital raise:
- Shares Offered: 59,459,460 shares of Common Stock.
- Over-Allotment Option: Underwriter granted an option to purchase up to 8,918,919 additional shares exercisable for 30 days.
- Expected Net Proceeds: Approximately $97.1 million (excluding proceeds from the over-allotment option).
- Costs: Proceeds are net of underwriting discounts, commissions, and estimated offering expenses.
Material Changes
The material change reported is the execution of an Underwriting Agreement with Cantor Fitzgerald & Co. This agreement facilitates a significant equity raise intended to increase the company's liquidity. The offering is being made pursuant to an effective shelf registration statement (Form S-3) filed previously.
Guidance, Outlook, and Risks
Outlook: The offering is expected to close on February 16, 2021. The company has agreed to provide customary indemnification rights to the underwriter.
Risks and Contingencies: The filing notes that the Underwriting Agreement contains customary representations, warranties, covenants, and conditions to closing. The description of the agreement is qualified by reference to the full text filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 16, 2021).
- Confirm the actual number of shares sold and whether the underwriter exercised the 8,918,919 share over-allotment option.
- Review the final prospectus supplement filed on February 16, 2021, for the exact offering price per share.
- Examine the full Underwriting Agreement (Exhibit 1.1) for specific conditions to closing and indemnification terms.
- Check subsequent filings to confirm the actual net proceeds received versus the estimated $97.1 million.